A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients With Active RA With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs (DMARD) Therapy Including Biologics.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients With Active RA With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs (DMARD) Therapy Including Biologics.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 20 Feb 2018 Results of pooled analysis of NCT00902486, NCT01469013, NCT01185353, NCT01721044, NCT01721057, NCT01711359, NCT01710358 and NCT01885078 trials assessing the effects of baricitinib on the lipid profile, lipoprotein particle size and number, and GlycA published in the Annals of the Rheumatic Diseases
    • 17 Jun 2017 Results assessing the incidence of serious infection events in Baricitinib treated RA patients from across eight studies (n=3492), presented at the 18th Annual Congress of the European League Against Rheumatism
    • 26 Oct 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top